Guarantor of the article: Michelle Segovia, PharmD.Specific author contributions: All authors contributed to drafting and revision of the letter and approved the letter's content before submission.Financial support: No funding or sponsorship was received for publication fees for this article. The manuscript referred to in the correspondence (Mahadevan U, et al) was an analysis of studies sponsored by Pfizer (NCT01465763, NCT01458951, NCT01458574, NCT03281304, NCT01470612, NCT00147498, NCT00847613, NCT00856544, NCT01039688, NCT02187055, NCT00413699, NCT00661661, NCT03502616, NCT02592434, NCT01500551, NCT01877668, NCT01882439, NCT03486457, NCT01976364, NCT01276639, NCT01309737, NCT01241591, NCT01186744, NCT01519089, NCT01815424, NCT01163253).Potential competing interests: Uma Mahadevan has received consulting fees from Abbvie, Boeringher Ingelheim, Bristol Myers Squibb, Celltrion, Enveda, Gilead, Janssen, Lilly, Merck, Pfizer Inc, Protagonist, Rani Therapeutics, Roivant, and Takeda. Michelle Segovia, Joseph Wu, Ivana Vranic, and Annette Diehl are employees and shareholders of Pfizer Inc. Arthur Kavanaugh has received consulting fees from Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB.
UM
Dr. Uma Mahadevan
Gastroenterology · Inflammatory Bowel DiseasesUniversity of California, San FranciscoumaSan Francisco, CA, USA
